Urtica dioica agglutinin (UDA) was tested for efficacy in a lethal SARS-CoV-infected BALB/c mouse model. UDA is a small plant monomeric lectin, 8.7 kDa in size, with an N-acetylglucosamine specificity and inhibits viruses from Nidovirales in vitro. In the current study, groups of BALB/c mice were infected with 2 LD50 of virus and treated intranasally with UDA at the doses of 20, 10, 5 and 0 mg/kg/day for 4 days beginning at 4 h post virus exposure. Treatment with UDA at 5 mg/kg significantly protected mice against a lethal infection with mouse-adapted SARS-CoV (*p*  \< 0.001), but did not significantly reduce virus lung titers. All mice receiving UDA treatments were also significantly protected against weight loss due to the infection (*p*  \< 0.001). UDA also effectively reduced lung pathology scores. All mice receiving poly IC:LC, the positive control drug, survived the infection (*p*  \< 0.001). At day 6 after virus exposure, all groups of mice receiving UDA or poly IC:LC had much lower lung weights than did the placebo-treated mice. Our data suggest that UDA treatment of SARS infection in mice leads to a substantial therapeutic effect that protects mice against death and weight loss.
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